# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-month review with the six-month liver cancer surveillance ultrasound and AFP. **S**

## History of present illness

Mr. Frazier returns nine weeks after his preventive visit. He has taken semaglutide 1 mg weekly for four months, with metformin, lisinopril, amlodipine and atorvastatin, without missed doses or side effects. Home readings average 124/78. He has had no alcohol since March. He has lost 6.8 kg since intake. He had the six-month liver ultrasound this morning. His PSA from the preventive visit was 1.4 ng/mL, which he was told by phone, and his colonoscopy is booked for next month. He has had no leg or abdominal swelling, black stools, confusion or yellowing. **S**

| Element | Detail |
|---|---|
| Semaglutide | 1 mg weekly for four months |
| Home blood pressure | Average 124/78 |
| Weight | 97.2 kg, down 6.8 kg (6.5%) |
| Alcohol | None since March |
| Screening | PSA 1.4 ng/mL; colonoscopy next month |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No abdominal swelling, black stools or nausea |
| Neurological | Negative | No confusion or sleep reversal |
| Cardiovascular | Negative | No ankle swelling |

3 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 97.2 kg; BMI 29.3 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 6.8% (high); Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.06 mg/dL; eGFR (CKD-EPI 2021, no race term): 78 mL/min/1.73 m²; Urine albumin-to-creatinine ratio: 14 mg/g; AST: 38 U/L; ALT: 31 U/L; Albumin: 4.1 g/dL; Total bilirubin: 0.8 mg/dL; Platelets: 140 10*3/uL (low); Alpha-fetoprotein (AFP): 4 ng/mL. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.4% (high) at baseline, 6.8% (high) at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.08 mg/dL at baseline, 1.06 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021, no race term): 77 mL/min/1.73 m² at baseline, 78 mL/min/1.73 m² at this visit **S**
- Urine albumin-to-creatinine ratio: 18 mg/g at baseline, 14 mg/g at this visit **S**
- AST: 48 U/L (high) at baseline, 38 U/L at this visit **S**
- ALT: 42 U/L at baseline, 31 U/L at this visit **S**
- Albumin: 4 g/dL at baseline, 4.1 g/dL at this visit **S**
- Total bilirubin: 0.9 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- Platelets: 138 10*3/uL (low) at baseline, 140 10*3/uL (low) at this visit **S**

## Immunizations given today

- Hepatitis A vaccine, adult, dose 2 of 2 **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**
- Influenza vaccine, inactivated, this season **S**
- COVID-19 vaccine, mRNA, this season **S**
- RSV vaccine, single dose **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 72; weight 97.2 kg, BMI 29.3 |
| Abdomen | Soft; no ascites |
| Skin | No jaundice |
| Neurological | No asterixis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Compensated cirrhosis from MASLD** (K74.69). Six-month surveillance ultrasound shows no focal lesion and AFP is 4.0 ng/mL. Albumin 4.1 g/dL, bilirubin 0.8 mg/dL and platelets 140; still Child-Pugh A. AST 38 and ALT 31 U/L after weight loss; FIB-4 3.12. Surveillance has been on time, which is what gives the best chance of finding a liver cancer early, when it can be cured. **S**
   - Next ultrasound with AFP in six months.
   - Results sent to Dr. Deshpande, who reviewed them and agrees; hepatology visit with repeat elastography at one year.
   - Repeat endoscopy in two years.
2. **Type 2 diabetes** (E11.65). A1c 6.8%, at goal, with no low blood sugar. Urine albumin-to-creatinine ratio 14 mg/g; creatinine 1.06 mg/dL, eGFR 78. **S**
   - Continue semaglutide 1 mg weekly and metformin.
   - A1c every six months now that he is at goal.
3. **Hypertension** (I10). At goal; potassium 4.5 on lisinopril. **S**
   - Continue the current medicines; kidney tests and potassium in six months.
4. **Obesity** (E66.811). 6.5% weight loss; BMI now 29.3. **S**
   - Continue toward 7 to 10%.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Completed today | Ultrasound: no focal lesion, no ascites, visualization score A; AFP 4.0 ng/mL; on schedule six months after the baseline |
| Laboratory | Liver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD) | At diagnosis, then every 6 months | Completed today | Albumin 4.1, bilirubin 0.8, platelets 140; Child-Pugh A |
| Laboratory | Liver tests with FIB-4 | Yearly with diabetes; FIB-4 1.3 or higher leads to elastography | Completed today | AST 38, ALT 31 U/L; FIB-4 3.12 |
| Imaging | Transient elastography | When FIB-4 is 1.3 or higher; repeat in 1 to 2 years | Due | Repeat at one year |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Up to date | No varices in April; repeat in two years |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Completed today | 6.8%, at goal |
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 122/76 in the clinic; home average 124/78; weight 97.2 kg |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2021) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Completed today | Sodium 140, potassium 4.5, creatinine 1.06 mg/dL, eGFR 78 |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Completed today | 14 mg/g |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Up to date | Dilated examination in June: no diabetic retinopathy |
| Examination | Comprehensive foot examination | Yearly | Up to date | At intake; next in February |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 68 mg/dL in April; yearly |
| Laboratory | Vitamin B12 on long-term metformin | Periodically on long-term metformin | Up to date | 340 pg/mL at intake |
| Medication safety | Aspirin for primary prevention | Yearly | Not indicated | Bleeding risk with cirrhosis outweighs benefit in primary prevention |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 1 mg weekly; no side effects |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol since March |
| Self-management | Warning signs of decompensation (swelling, confusion, bleeding, jaundice) | Every visit | Completed today | Reviewed; none |
| Self-management | Vaccines for diabetes and chronic liver disease | As due | Completed today | Hepatitis A dose 2, second zoster dose, influenza, COVID-19 and RSV vaccines today |

## Goal progress

- A1c below 7% within six to nine months, without low blood sugar. Outcome by 2026-09-14: 8.4% to 6.8% at seven months; no low blood sugar. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home. Outcome by 2026-09-14: 122/76 in the clinic; home average 124/78. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-13: 132 to 68 mg/dL on atorvastatin. **S**
- Weight loss of 7 to 10% for liver health within a year. Outcome by 2026-09-14: 104.0 to 97.2 kg (6.5%) at seven months. **S**
- Liver cancer surveillance by ultrasound with AFP every six months, on time. Outcome by 2026-09-14: Baseline and six-month ultrasounds with AFP on schedule; no focal lesion; AFP 4.2 and 4.0 ng/mL. **S**
- No alcohol, to protect the liver. Outcome by 2026-09-14: No alcohol since the two-week visit. **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023), American Association for the Study of Liver Diseases (Hepatology 2023;77(5))
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology 2023;78(6))
- Baveno VII - Renewing consensus in portal hypertension (2022), Baveno VII Faculty (Journal of Hepatology 2022;76(4))
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Visit in three months. Ultrasound with AFP in six months; hepatology visit with elastography at one year. A1c every six months. Colonoscopy next month. Preventive visit in one year. **S**

